Chinese innovator Shenogen raises new funds for ER-a36 platform
This article was originally published in Scrip
With the $30 million it has just raised in a Series C financing, the Chinese drug development venture Shenogen Pharma Group is aiming to take its lead pipeline project through a Phase II proof-of-concept trial for advanced hepatocellular carcinoma (HCC).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.